CALLIDITAS THERAPEUTICS-ADR (CALT)
US13124Q1067 - ADR
CALT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of CALT have multiple concerns. CALT shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
CALT had negative earnings in the past year.
CALT had a negative operating cash flow in the past year.
In the past 5 years CALT always reported negative net income.
In the past 5 years CALT always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -25.07%, CALT is in line with its industry, outperforming 59.49% of the companies in the same industry.
CALT has a Return On Equity of -139.24%. This is in the lower half of the industry: CALT underperforms 67.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -25.07% | ||
| ROE | -139.24% | ||
| ROIC | N/A |
ROA(3y)-26.82%
ROA(5y)-22.62%
ROE(3y)-80.89%
ROE(5y)-56.52%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CALT has a better Gross Margin (94.99%) than 96.41% of its industry peers.
The Profit Margin and Operating Margin are not available for CALT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 94.99% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CALT does not have a ROIC to compare to the WACC, probably because it is not profitable.
CALT has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for CALT has been increased compared to 5 years ago.
Compared to 1 year ago, CALT has a worse debt to assets ratio.
2.2 Solvency
CALT has a Debt/Equity ratio of 2.89. This is a high value indicating a heavy dependency on external financing.
CALT has a worse Debt to Equity ratio (2.89) than 84.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.89 | ||
| Debt/FCF | N/A | ||
| Altman-Z | N/A |
ROIC/WACCN/A
WACC6.94%
2.3 Liquidity
A Current Ratio of 3.13 indicates that CALT has no problem at all paying its short term obligations.
CALT's Current ratio of 3.13 is in line compared to the rest of the industry. CALT outperforms 49.23% of its industry peers.
A Quick Ratio of 3.08 indicates that CALT has no problem at all paying its short term obligations.
With a Quick ratio value of 3.08, CALT perfoms like the industry average, outperforming 52.31% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.13 | ||
| Quick Ratio | 3.08 |
3. Growth
3.1 Past
The earnings per share for CALT have decreased strongly by -11.20% in the last year.
CALT shows a strong growth in Revenue. In the last year, the Revenue has grown by 50.32%.
CALT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 1013.57% yearly.
EPS 1Y (TTM)-11.2%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-385.71%
Revenue 1Y (TTM)50.32%
Revenue growth 3Y1013.57%
Revenue growth 5YN/A
Revenue growth Q2Q5.25%
3.2 Future
The Earnings Per Share is expected to grow by 98.67% on average over the next years. This is a very strong growth
CALT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 45.13% yearly.
EPS Next Y146.48%
EPS Next 2Y106.78%
EPS Next 3Y81.58%
EPS Next 5Y98.67%
Revenue Next Year69.12%
Revenue Next 2Y70.6%
Revenue Next 3Y59.84%
Revenue Next 5Y45.13%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CALT. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 26.41, CALT can be considered very expensive at the moment.
80.00% of the companies in the same industry are more expensive than CALT, based on the Price/Forward Earnings ratio.
CALT is valuated rather expensively when we compare the Price/Forward Earnings ratio to 21.35, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 26.41 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CALT's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as CALT's earnings are expected to grow with 81.58% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y106.78%
EPS Next 3Y81.58%
5. Dividend
5.1 Amount
No dividends for CALT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CALLIDITAS THERAPEUTICS-ADR
NASDAQ:CALT (4/26/2024, 7:00:00 PM)
19.5006
+0.05 (+0.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap523.32M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 26.41 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -25.07% | ||
| ROE | -139.24% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 94.99% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.65
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.89 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.13 | ||
| Quick Ratio | 3.08 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-11.2%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y146.48%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)50.32%
Revenue growth 3Y1013.57%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y